KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Other financing activities (2016 - 2025)

Historic Other financing activities for Eli Lilly (LLY) over the last 15 years, with Q4 2025 value amounting to -$25.1 million.

  • Eli Lilly's Other financing activities rose 4531.59% to -$25.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$772.0 million, marking a year-over-year decrease of 5723.01%. This contributed to the annual value of -$772.0 million for FY2025, which is 5723.01% down from last year.
  • Eli Lilly's Other financing activities amounted to -$25.1 million in Q4 2025, which was up 4531.59% from -$30.2 million recorded in Q3 2025.
  • Eli Lilly's 5-year Other financing activities high stood at -$500000.0 for Q3 2021, and its period low was -$686.3 million during Q1 2025.
  • Moreover, its 5-year median value for Other financing activities was -$27.6 million (2025), whereas its average is -$110.1 million.
  • Its Other financing activities has fluctuated over the past 5 years, first surged by 9855.07% in 2021, then tumbled by 218333.33% in 2022.
  • Quarter analysis of 5 years shows Eli Lilly's Other financing activities stood at -$600000.0 in 2021, then crashed by 2183.33% to -$13.7 million in 2022, then plummeted by 130.66% to -$31.6 million in 2023, then tumbled by 45.25% to -$45.9 million in 2024, then surged by 45.32% to -$25.1 million in 2025.
  • Its Other financing activities was -$25.1 million in Q4 2025, compared to -$30.2 million in Q3 2025 and -$30.4 million in Q2 2025.